Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Long Beach Center for Clinical Research

Neither a doctor nor a teaching hospital

Research payments

$572,304

106 payments

Through program year 2025, Long Beach Center for Clinical Research is reported as receiving $572,304 in research payments, across 106 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $17,000 3
2023 Research $12,674 3
2022 Research $3,066 2
2021 Research $1,688 3
2020 Research $175,156 35
2019 Research $362,721 60

Breakdown

Who paid Research payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $131,169 3 payments
  2. Amgen Inc. $121,553 8 payments
  3. Akcea Therapeutics, Inc. $102,276 8 payments
  4. Sanofi US Services Inc. $96,991 27 payments
  5. AstraZeneca Pharmaceuticals LP $65,182 14 payments
  6. Grifols Shared Services North America, Inc. $17,000 3 payments
  7. Esperion Therapeutics, Inc. $12,674 3 payments
  8. AstraZeneca UK Limited $12,406 2 payments
  9. Novo Nordisk AS $7,094 23 payments
  10. Boehringer Ingelheim International GmbH $3,330 14 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Multicenter Randomized Double Blind Active Controlled Study to Evaluate the Effects of Lcz696 Compared to Valsartan on Cognitive Function As Assessed By Comprehensive Neurocognitive Battery and Brain Amyloid Plaque Deposition As Assessed By PET Imaging $130,489 2 payments
  2. FOURIER OLE (Ph 4) $121,472 6 payments
  3. Isis 678354-Cs2 $79,962 6 payments
  4. A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular Risk $40,550 8 payments
  5. A Long Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridemia $38,010 6 payments
  6. A Phase 2b Multicenter Randomised Double blind Placebo controlled Study of Verinurad and Allopurinol in Patients with Chronic Kidney Disease and Hyperuricemia $28,408 8 payments
  7. A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Phase 2 Study of ISIS 678354 Administered Subcutaneously to Patients With Hypertriglyceridemia and Established Cardiovascular Disease (CVD) or at a High Risk for CVD $22,314 2 payments
  8. A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 Administered as a Single Ascending Dose and Multiple Ascending Doses in Participants With Chronic Hepatitis B Virus Infection $17,000 3 payments
  9. A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function $14,912 9 payments
  10. A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Effects of Bempedoic Acid (Etc-1002) on the Occurrence of Major Cardiovascular Events in Patients With, Or at High Risk For, Cardiovascular Disease Who Are Statin Intolerant $12,674 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record